604 related articles for article (PubMed ID: 8970360)
1. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
[TBL] [Abstract][Full Text] [Related]
2. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
3. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
4. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
[TBL] [Abstract][Full Text] [Related]
5. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
6. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
Wheless SA; Gulley ML; Raab-Traub N; McNeillie P; Neuringer IP; Ford HJ; Aris RM
Am J Respir Crit Care Med; 2008 Nov; 178(10):1060-5. PubMed ID: 18755927
[TBL] [Abstract][Full Text] [Related]
7. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients.
Shapiro NL; Tang CG; Bhattacharyya N
Laryngoscope; 2011 Aug; 121(8):1718-25. PubMed ID: 21792960
[TBL] [Abstract][Full Text] [Related]
8. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
Malouf MA; Chhajed PN; Hopkins P; Plit M; Turner J; Glanville AR
J Heart Lung Transplant; 2002 May; 21(5):547-54. PubMed ID: 11983544
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
Muchtar E; Kramer MR; Vidal L; Ram R; Gurion R; Rosenblat Y; Bakal I; Shpilberg O
Transplantation; 2013 Oct; 96(7):657-63. PubMed ID: 23823652
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
Leyssens A; Dierickx D; Verbeken EK; Tousseyn T; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verleden GM; Van Raemdonck DE; Vos R
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28383790
[TBL] [Abstract][Full Text] [Related]
11. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
[TBL] [Abstract][Full Text] [Related]
12. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH
J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416
[TBL] [Abstract][Full Text] [Related]
14. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
15. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
[TBL] [Abstract][Full Text] [Related]
16. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
18. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
19. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center.
Angel LF; Cai TH; Sako EY; Levine SM
Ann Transplant; 2000; 5(3):26-30. PubMed ID: 11147026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
